ASS1 as a novel tumor suppressor gene in myxofibrosarcomas: Aberrant loss via epigenetic DNA methylation confers aggressive phenotypes, negative prognostic impact, and therapeutic relevance

Clinical Cancer Research

Volumn 19, Issue 11, 2013, Pages 2861-2872

  Huang, Hsuan Ying ^a   Wu, Wen Ren ^b   Wang, Yu Hui ^f   Wang, Jun Wen ^a   Fang, Fu Min ^a   Tsai, Jen Wei ^c   Li, Shau Hsuan ^a   Hung, Hsiao Chin ^a   Yu, Shih Chen ^a   Lan, Jui ^a   Shiue, Yow Ling ^b   Hsing, Chung His ^g   Chen, Li Tzong ^d,f,h   Li, Chien Feng ^b,d,e,g,h,i  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

^c E DA HOSPITAL   (Taiwan)

^d KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^e KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^f NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^g CHI MEI MEDICAL CENTER   (Taiwan)

^h NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

ⁱ SOUTHERN TAIWAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ARGININE DEIMINASE; ARGININE DERIVATIVE; ARGININOSUCCINATE SYNTHASE; ARGININOSUCCINATE SYNTHASE 1; CYCLIN E; GELATINASE B; UNCLASSIFIED DRUG;

ADULT; AMINO ACID METABOLISM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ARTICLE; ASS1 GENE; CANCER CELL CULTURE; CANCER GRADING; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CELL PROLIFERATION; CELL VIABILITY; CLINICAL ARTICLE; CORRELATION ANALYSIS; DNA METHYLATION; DOSE RESPONSE; ENZYME INHIBITION; ENZYME REGULATION; ENZYME REPRESSION; EPIGENETICS; FEMALE; FIBROSARCOMA; G1 PHASE CELL CYCLE CHECKPOINT; GENE SEQUENCE; GENETIC REGULATION; HUMAN; HUMAN CELL; MALE; MOUSE; MYXOFIBROSARCOMA; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; PYROSEQUENCING; S PHASE CELL CYCLE CHECKPOINT; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

ADULT; AGED; AMINO-ACID N-ACETYLTRANSFERASE; ANIMALS; ARGININOSUCCINATE SYNTHASE; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; CLUSTER ANALYSIS; DNA METHYLATION; FEMALE; FIBROSARCOMA; G1 PHASE CELL CYCLE CHECKPOINTS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; GENES, TUMOR SUPPRESSOR; HUMANS; HYDROLASES; LEIOMYOSARCOMA; MALE; MICE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; PHENOTYPE; POLYETHYLENE GLYCOLS; PROGNOSIS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84878983669     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-2641     Document Type: Article

References (39)

1. Lin CN, Chou SC, Li CF, Tsai KB, Chen WC, Hsiung CY, et al. Prognostic factors of myxofibrosarcomas: implications of margin status, tumor necrosis, and mitotic rate on survival. J Surg Oncol 2006;93:294-303.
2. Mentzel T, Calonje E, Wadden C, Camplejohn RS, Beham A, Smith MA, et al. Myxo fibrosarcoma. Clinicopathologic analysis of 75 cases with emphasis on the low-grade variant. Am J Surg Pathol 1996;20:391-405. (Pubitemid 26113344)
3. Mutter RW, Singer S, Zhang Z, Brennan MF, Alektiar KM. The enigma of myxofibrosarcoma of the extremity. Cancer 2012;118:518 -27.
4. Li CF, Wang JM, Kang HY, Huang CK, Wang JW, Fang FM, et al. Characterization of gene amplification-driven SKP2 overexpression in myxofibrosarcoma: potential implications in tumor progression and therapeutics. Clin Cancer Res 2012;18:1598-610.
5. Willems SM, Debiec-Rychter M, Szuhai K, Hogendoorn PC, Sciot R. Local recurrence of myxofibrosarcoma is associated with increase in tumour grade and cytogenetic aberrations, suggesting a multistep tumour progression model. Mod Pathol 2006;19:407-16. (Pubitemid 43276995)
6. Oda Y, Takahira T, Kawaguchi K, Yamamoto H, Tamiya S, Matsuda S, et al. Altered expression of cell cycle regulators in myxofibrosarcoma, with special emphasis on their prognostic implications. Hum Pathol 2003;34:1035-42. (Pubitemid 37315256)
7. Sanfilippo R, Miceli R, Grosso F, Fiore M, Puma E, Pennacchioli E, et al. Myxofibrosarcoma: prognostic factors and survival in a series of patients treated at a single institution. Ann Surg Oncol 2011;18:720-5.
8. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74.
9. Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. Nat Rev Cancer 2011;11:85-95.
10. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer 2004;4:891-9. (Pubitemid 39472955)
11. Liu X, Wang X, Zhang J, Lam EK, Shin VY, Cheng AS, et al. Warburg effect revisited: an epigenetic link between glycolysis and gastric carcinogenesis. Oncogene 2010;29:442-50.
12. Smerc A, Sodja E, Legisa M. Posttranslational modification of 6-phosphofructo-1-kinase as an important feature of cancer metabolism. PLoS ONE 2011;6:e19645.
13. Barretina J, Taylor BS, Banerji S, Ramos AH, Lagos-Quintana M, Decarolis PL, et al. Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet 2010;42:715- 21.
14. Snijders AM, Nowak N, Segraves R, Blackwood S, Brown N, Conroy J, et al. Assembly of microarrays for genome-wide measurement of DNA copy number. Nat Genet 2001;29:263-4. (Pubitemid 33096449)
15. Tennant DA, Duran RV, Gottlieb E. Targeting metabolic transformation for cancer therapy. Nat Rev Cancer 2010;10:267-77.
16. Pieters R, Hunger SP, Boos J, Rizzari C, Silverman L, Baruchel A, et al. L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase. Cancer 2011;117:238-49.
17. Husson A, Brasse-Lagnel C, Fairand A, Renouf S, Lavoinne A. Argininosuccinate synthetase from the urea cycle to the citrulline-NO cycle. Eur J Biochem 2003;270:1887-99. (Pubitemid 36560809)
18. Dillon BJ, Prieto VG, Curley SA, Ensor CM, Holtsberg FW, Bomalaski JS, et al. Incidence and distribution of argininosuccinate synthetase deficiency in human cancers: a method for identifying cancers sensitive to arginine deprivation. Cancer 2004;100:826-33. (Pubitemid 38176863)
19. Wheatley DN. Arginine deprivation and metabolomics: important aspects of intermediary metabolism in relation to the differential sensitivity of normal and tumour cells. Semin Cancer Biol 2005;15:247-53. (Pubitemid 41058771)
20. Delage B, Fennell DA, Nicholson L, McNeish I, Lemoine NR, Crook T, et al. Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer. Int J Cancer 2010;126:2762-72.
21. Yang TS, Lu SN, Chao Y, Sheen IS, Lin CC, Wang TE, et al. A randomised phase II study of pegylated arginine deiminase (ADI-PEG 20) in Asian advanced hepatocellular carcinoma patients. Br J Cancer 2010;103:954-60.
22. Kawashima H, Ogose A, Gu W, Nishio J, Kudo N, Kondo N, et al. Establishment and characterization of a novel myxofibrosarcoma cell line. Cancer Genet Cytogenet 2005;161:28-35. (Pubitemid 41096048)
23. Krause AK, Hinrichs SH, Orndal C, DeBoer J, Neff JR, Bridge JA. Characterization of a human myxoid malignant fibrous histiocytoma cell line, OH931. Cancer Genet Cytogenet 1997;94:138-43. (Pubitemid 27169348)
24. Lee JC, Li CF, Fang FM, Wang JW, Jeng YM, Yu SC, et al. Prognostic implication of MET overexpression in myxofibrosarcomas: an integrative array comparative genomic hybridization, real-time quantitative PCR, immunoblotting, and immunohistochemical analysis. Mod Pathol 2010;23:1379-92.
25. Ariizumi T, Ogose A, Kawashima H, Hotta T, Umezu H, Endo N. Multinucleation followed by an acytokinetic cell division in myxofibrosarcoma with giant cell proliferation. J Exp Clin Cancer Res 2009;28:44.
26. Huang HY, Li CF, Fang FM, Tsai JW, Li SH, Lee YT, et al. Prognostic implication of ezrin overexpression in myxofibrosarcomas. Ann Surg Oncol 2010;17:3212-9.
27. Szlosarek PW, Klabatsa A, Pallaska A, Sheaff M, Smith P, Crook T, et al. In vivo loss of expression of argininosuccinate synthetase in malignant pleural mesothelioma is a biomarker for susceptibility to arginine depletion. Clin Cancer Res 2006;12:7126-31. (Pubitemid 44974513)
28. Huang HY, Kang HY, Li CF, Eng HL, Chou SC, Lin CN, et al. Skp2 overexpression is highly representative of intrinsic biological aggressiveness and independently associated with poor prognosis in primary localized myxofibrosarcomas. Clin Cancer Res 2006;12:487-98.
29. Nicholson LJ, Smith PR, Hiller L, Szlosarek PW, Kimberley C, Sehouli J, et al. Epigenetic silencing of argininosuccinate synthetase confers resistance to platinum-induced cell death but collateral sensitivity to arginine auxotrophy in ovarian cancer. Int J Cancer 2009;125:1454-63.
30. Nyberg P, Xie L, Kalluri R. Endogenous inhibitors of angiogenesis. Cancer Res 2005;65:3967-79. (Pubitemid 40775631)
31. Coindre JM, Terrier P, Guillou L, Le Doussal V, Collin F, Ranchere D, et al. Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas: a study of 1240 patients from the French Federation of Cancer Centers Sarcoma Group. Cancer 2001;91:1914-26. (Pubitemid 32424119)
32. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30. (Pubitemid 40310185)
33. Huang HY, Lal P, Qin J, Brennan MF, Antonescu CR. Low-grade myxofibrosarcoma: a clinicopathologic analysis of 49 cases treated at a single institution with simultaneous assessment of the efficacy of 3-tier and 4-tier grading systems. Hum Pathol 2004;35:612-21. (Pubitemid 38656947)
34. Haglund KE, Raut CP, Nascimento AF, Wang Q, George S, Baldini EH. Recurrence patterns and survival for patients with intermediate- and high-grade myxofibrosarcoma. Int J Radiat Oncol Biol Phys 2012;82:361-7.
35. Delage B, Luong P, Maharaj L, O'Riain C, Syed N, Crook T, et al. Promoter methylation of argininosuccinate synthetase-1 sensitises lymphomas to arginine deiminase treatment, autophagy and caspase-dependent apoptosis. Cell Death Dis 2012;3:e342.
36. Kobayashi E, Masuda M, Nakayama R, Ichikawa H, Satow R, Shitashige M, et al. Reduced argininosuccinate synthetase is a predictive biomarker for the development of pulmonary metastasis in patients with osteosarcoma. Mol Cancer Ther 2010;9:535-44.
37. Bauvois B. New facets of matrix metalloproteinases MMP-2 and MMP-9 as cell surface transducers: outside-in signaling and relationship to tumor progression. Biochim Biophys Acta 2012;1825:29-36.
38. Xu J, Rodriguez D, Petitclerc E, Kim JJ, Hangai M, Moon YS, et al. Proteolytic exposure of a cryptic site within collagen type IV is required for angiogenesis and tumor growth in vivo. J Cell Biol 2001;154:1069-79. (Pubitemid 34286185)
39. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002;2:161-74. (Pubitemid 37328786)